B1Q Stock Chart & Stats
€3.00
-€0.18(-5.30%)
At close: 4:00 PM EDT
€3.00
-€0.18(-5.30%)
Day’s Range― - ―
52-Week Range€1.37 - €4.13
Previous CloseN/A
Volume0.00
Average Volume (3M)32.00
Market Cap
€101.38M
Enterprise Value€128.55M
Total Cash (Recent Filing)€26.69M
Total Debt (Recent Filing)€1.25M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 16, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding43,295,770
10 Day Avg. Volume62
30 Day Avg. Volume32
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.64
Price to Sales (P/S)47.35
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€31.22Price Target Upside940.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.79
Revenue Forecast (FY)€5.06M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressThe FDA’s reclassification indicates that review has advanced with reduced agency resource requirements, while the remaining issue is narrower than a drug-related deficiency. Resolution could support a 2026 launch and establish a commercial foothold in a recognized shortage market.
Strategic ContractThe DARPA prime contract provides external funding, validation, and a defined clinical program for combining NRX-101 with robotic TMS. Retained ownership of new inventions may preserve longer-term strategic value while the trial targets treatment-resistant depression and military applications.
Expanded PipelineAdding two clinical-stage antibodies diversifies NRXP beyond its ketamine and depression programs, creating multiple potential development paths and reducing reliance on a single candidate. The broader portfolio may support future partnerships, funding opportunities, and indications if clinical milestones are achieved.
Bears Say
Persistent LossesRevenue growth has not yet produced operating profitability, as expenses remain far above the current commercial base and margins have weakened during the ramp. Continued losses reduce internally generated funding and make successful regulatory and commercial execution increasingly important.
Cash BurnSustained negative operating and free cash flow means NRXP is consuming capital to fund development and operations rather than self-financing growth. Unless revenue expands materially or costs decline, the company will likely require additional financing to maintain its programs.
Execution UncertaintyThe investment case depends on several external milestones, including ketamine and NDA approvals and finalization of military contracting. Delays, unfavorable decisions, or incomplete agreements could defer commercialization, interrupt trial plans, and increase the capital required to reach later-stage objectives.
NRX Pharmaceuticals News
B1Q FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was €1.37 and its highest was €4.13 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is €101.38M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Nov 16, 2026 which is in 24 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on Aug 17, 2026. The company reported -€0.392 earnings per share for the quarter, missing the consensus estimate of -€0.095 by -€0.297.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.19.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 43,295,770 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -€0.392 in its last earnings report, missing expectations of -€0.095. Following the earnings report the stock price went up 7.504%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:B1Q
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€31.22 (940.71% Upside)
€31.22 (940.71% Upside)
Blogger Sentiment
Bearish
DE:B1Q Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.80%
12-Months-Change
Fundamentals
Return on Equity
168.68%
Trailing 12-Months
Asset Growth
606.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
B1Q Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed significant strategic and technical progress across multiple fronts: near-term commercialization steps (ANDA and launch-stock orders), a strengthened balance sheet (cash up ~242%), a materially expanded development pipeline via the GeNeuro acquisition, and a high-impact DARPA/military partnership with a 400-patient SPARC-TMS trial. These positives are tempered by ongoing net operating losses (operating loss up ~48.7%), regulatory/contracting uncertainties, dependence on nondilutive government funding, and the need for further financing or successful commercial milestones beyond the ~1-year cash runway. Overall, the tone is cautiously optimistic: strong strategic wins and funding momentum outweigh current financial and execution risks, but key approvals, contracts and trial execution remain critical near-term milestones.View all DE:B1Q earnings summariesB1Q Stock 12 Month Forecast
Average Price Target
€31.22
▲(940.71% Upside)
Technical Analysis
CervoMed
―
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―